Last reviewed · How we verify
Mindfulness-based Dementia Care Partner Program to Reduce Depressive Symptoms
NA trial testing Mindfulness-Based Dementia Caregiving in Dementia in 130 participants. Completed in 20 March 2024.
| Lead sponsor | HealthPartners Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 130 |
| Start date | 7 November 2022 |
| Primary completion | 15 December 2023 |
| Estimated completion | 20 March 2024 |
| Sites | 1 location across United States |
HealthPartners Institute
18 and older, any sex, with Dementia. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of the participants who attend the first class of their session. Enrolled is defined as a participant who is assigned to a course. Range \[0-124\]. A value closer to 124 is indicative of greater feasibility.
| Group | Value | 95% CI |
|---|---|---|
| MBDC Course | 84 |
Percent of the participants who completed courses. Completion is defined as attending a minimum of 6 of the 9 classes. Range \[0-100\]. A value closer to 100 is indicative of greater feasibility.
| Group | Value | 95% CI |
|---|---|---|
| MBDC Course | 94.0 |
Completeness of questionnaires given over the course of the study. Completeness is defined percent of complete questionnaires.
| Group | Value | 95% CI |
|---|---|---|
| MBDC Course | 96.8 | ± 2.2 |
Measured using Zarit Burden Interview (ZBI-6). Total of 6 questions scored on a 5 point scale (0-4). The sum of the 6 questions in the total score. Range: 0-24. A higher score is indicative of greater caregiver burden. Change in control period compared to change in intervention period.
| Group | Value | 95% CI |
|---|---|---|
| MBDC Course | -1.1 | -2 – -0.2 |
| Group | Value | 95% CI |
|---|---|---|
| MBDC Course | -0.8 | -1.8 – 0.2 |
Measured using the Center for Epidemiological Studies Depression Scale (CES-D-10). Total of 10 questions scored on a categorical scale (0-3). The sum of the 10 questions is the total score. Range: 0-30. A total value above 10 is considered to be a sign of depression. A higher score represents a greater degree of depressed mood. Change in control period compared to change in intervention period.
| Group | Value | 95% CI |
|---|---|---|
| MBDC Course | 0.11 | 0.03 – 0.4 |
| Group | Value | 95% CI |
|---|---|---|
| MBDC Course | 0.09 | 0.02 – 0.36 |
Measured using "The State Self-Compassion Scale Short Form." Uses a Likert-type scale ranging from 1 to 5. \[Range: 12-60\] Higher scores indicates more self compassion.
| Group | Value | 95% CI |
|---|---|---|
| MBDC Course | 0.4 | 0.2 – 0.5 |
| Group | Value | 95% CI |
|---|---|---|
| MBDC Course | 0.4 | 0.2 – 0.6 |
Measured using The 5-Item Mindful Attention Awareness Scale - State This is a 5-item scale to indicate at what level they relate to specific experiences, aimed at measuring main characteristics of mindfulness: (scale is 0-"not at all" to 6-"very much"). \[Range: 0-30\] Higher scores indicate elevated levels of mindfulness expression.
| Group | Value | 95% CI |
|---|---|---|
| MBDC Course | 0.3 | -0.1 – 0.6 |
| Group | Value | 95% CI |
|---|---|---|
| MBDC Course | 0.5 | 0.2 – 0.9 |
The purpose of this study is to assess the feasibility, acceptability, and fidelity of implementation of the Mindfulness Based Dementia Care (MBDC) program to reduce depressive symptoms in care partners (CPs) of people living with dementia (PLWD).
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
Currently open trials in the same condition.
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05617300.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing